Fig. 5 | Signal Transduction and Targeted Therapy

Fig. 5

From: A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants

Fig. 5

In vivo pharmacokinetics and safety data of SY110.SY110 was administered by intravenous injection (i.v.) or oral gavage (p.o.) route, then the blood samples of the dogs (a), monkeys (b), and mice (c) were analyzed. The two dash lines in (c) indicate the EC50 and EC90 values for SY110 against BA.2 variant (Fig. 3b). d The weight change (percentage of initial weight) of mice treated with SY110 by oral administration for two weeks (n = 6)

Back to article page